Search results for "treatment options"

showing 10 items of 88 documents

Ovarian Cancer: Primary Advanced and Recurrent Disease

2021

Approximately 70% of patients affected by epithelial ovarian cancer (EOC) are diagnosed with FIGO stage III–IV disease and 50–70% of them will develop a recurrence, after a median progression-free survival (PFS) of approximately 18 months. The 5-year survival for stage III and IV ranges from 39% to 17%, respectively. Treatment options for primary advanced and recurrent disease comprehend surgery (primary cytoreductive surgery or interval cytoreductive surgery after neoadjuvant chemotherapy for primary advanced disease and secondary cytoreductive surgery for recurrent disease) and systemic therapy (standard and novel chemotherapeutic agents and biological agents).

Oncologymedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentTreatment optionsDiseasemedicine.diseaseSystemic therapyInternal medicinemedicineRecurrent diseaseEpithelial ovarian cancerStage (cooking)businessOvarian cancer
researchProduct

Treatment sequence of synchronously (liver) metastasized colon cancer

2016

No standards for staging, systemic therapy or the timing of an operation are defined for patients newly diagnosed with synchronous metastases and a primary in the colon. An expert group of radiologists, medical, radiation and surgical oncologists therefore came together to discuss staging and treatment sequence for these patients and came up with a recommendation based on current evidence of potential therapeutic options. The discussion was organized to debate recommendations centred on 5 topics and therefore the position paper is built upon these titles and their subtitles. Editrice Gastroenterologica Italiana S.r.l.

Oncologymedicine.medical_specialtyColonColorectal cancermedicine.medical_treatment030230 surgeryTreatment sequenceSystemic therapy03 medical and health sciencesLiver metastases0302 clinical medicinePharmacotherapyDrug TherapyInternal medicinemedicineHepatectomyHumansCombined Modality TherapyTreatment optionsNeoplasm StagingHepatologybusiness.industryGeneral surgeryLiver NeoplasmsGastroenterologyAntineoplastic Protocolsmedicine.diseaseCombined Modality TherapyExpert groupColorectal cancerLiver030220 oncology & carcinogenesisPosition paperHepatectomyColorectal NeoplasmsbusinessSynchronous presentation
researchProduct

Transarterial radioembolization for hepatocellular carcinoma: a review

2016

Rodolfo Sacco,1 Caterina Conte,2 Emanuele Tumino,1 Giuseppe Parisi,1 Sara Marceglia,3 Salvatore Metrangolo,1 Roberto Eggenhoffner,4 Giampaolo Bresci,1 Giuseppe Cabibbo,5 Luca Giacomelli4 1Department of Gastroenterology, Cisanello Hospital, Pisa, 2Endocrinology and Metabolic Diseases, Policlinico A. Gemelli, Università Cattolica del Sacro Cuore, Rome, 3Department of Engineering and Architecture, University of Trieste, Trieste, 4Department of Surgical Sciences and Integrated Diagnostics, School of Medicine, Genova University, Genoa, 5Section of Gastroenterology, DIBIMIS, University of Palermo, Palermo, Italy Abstract: Hepatocellular carcinoma (HCC) is the most common type of liver canc…

Oncologymedicine.medical_specialtyReviewTransarterial RadioembolizationMalignancylcsh:RC254-28203 medical and health sciences0302 clinical medicineInternal medicineMedicineTherapeutic strategyCause of deathbusiness.industryTreatment optionshepatocellular carcinomahepatocellular carcinoma; transarterial radioembolizationmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensdigestive system diseasesSafety profile030220 oncology & carcinogenesisHepatocellular carcinomatransarterial radioembolization030211 gastroenterology & hepatologybusinessLiver cancerhepatocellular carcinoma transarterial radioembolization
researchProduct

Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy?

2014

Introduction: Treatment of ovarian cancer has been long standardized with the inclusion of surgery and chemotherapy based on platinum and taxanes, this strategy reaching high remission rates. However, when this treatment fails, further options are available with little benefit. Since ovarian cancer has specific immunologic features, actually immunotherapy is under evalua- 15 tion to overcome treatment failure in patients experiencing recurrence. Areas covered: Immunogenicity of ovarian cancer and its relationship with clinical outcomes is briefly reviewed. The kinds of immunotherapeutic strategies are summarized. The clinical trials investigating immunotherapy in recurrent ovarian cancer pa…

Oncologymedicine.medical_specialtySettore MED/06 - Oncologia Medicamedicine.medical_treatmentClinical BiochemistryTreatment failureInternal medicineDrug DiscoverymedicineAnimalsHumansIn patientTreatment FailureBiologyOvarian Neoplasmsantibody cancer vaccines cell transfer immune system immunotherapy ovarian cancer recurrence treatment strategiesPharmacologyChemotherapybusiness.industryTreatment optionsImmunotherapymedicine.diseaseClinical trialRecurrent Ovarian CancerImmunologyFemaleImmunotherapyHuman medicineNeoplasm Recurrence LocalOvarian cancerbusinessEngineering sciences. TechnologyExpert Opinion on Biological Therapy
researchProduct

Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus?

2012

Mantle Cell Lymphoma (MCL) is associated with a dismal prognosis. Recently, along with the improved understanding of the pathophysiology of this disease, new first line regimens have been established and in addition novel treatment options have entered the clinical arena. In consequence, prognosis of the disease has fortunately improved. We here focus on the rationale, current clinical knowledge and future concepts of Temsirolimus, an inhibitor of mTOR, in the treatment of MCL. At this time this drug has been shown to be effective as single agent for relapsed disease and early combination data show promising results. In addition, with a brief outline of other treatment options, we aim to g…

Oncologymedicine.medical_specialtybusiness.industryFirst linemantle cell lymphomaCancerTreatment optionsmTOR-inhibitorReviewDiseasemedicine.diseaseBioinformaticslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282TemsirolimusClinical knowledgeOncologyInternal medicinetemsirolimusmedicineRefractory Mantle Cell LymphomaMantle cell lymphomabusinessmedicine.drugClinical Medicine Insights: Oncology
researchProduct

A skeletal Class III malocclusion with agenesis and canine-bicuspid transposition: a nonsurgical approach

2021

Abstract Background The present case report describes the orthodontic management of a patient who presented with a skeletal Class III malocclusion combined with other dental anomalies. The malocclusion was complicated by agenic maxillary lateral incisors and a lower right second premolar, in company with the transposition of the maxillary canines and premolars. Methods Dentoalveolar compensation of the anteroposterior jaw relationship was performed. The upper deciduous lateral incisors were extracted and the spaces closed, so that the first premolars replaced the missing lateral incisors while the canine transposition was maintained Results Satisfactory results were obtained which provided …

OrthodonticsDental anomaliesSurgical approachbusiness.industryTreatment optionsOrthodonticsSkeletal classmedicine.diseaseTransposition (music)medicine.anatomical_structureAgenesisDentistry Oral Surgery & MedicinePremolarMedicineMalocclusionbusinessAustralasian Orthodontic Journal
researchProduct

Treatment of Class III malocclusion using Hybrid Hyrax, Face Mask and Alt-RAMEC Protocol : a case report in a latin-american patient

2019

The management of Class III malocclusion is one of the greatest challenges of orthodontics. Current treatments offer the possibility of using direct skeletal anchorage to improve clinical outcomes. This case shows the results of using a Hyrax hybrid palatal anchorage, Alt-RAMEC (Alternate Rapid Maxillary Expansion and Contraction protocol) and a facemask to treat a maxillary hypoplasia Class III malocclusion in a Latin-American patient. The appliance design and the protocol used are widely described. Clinical and cephalometric results suggest that it is a good treatment option for this Latino patient, with moderate malocclusion and limitations in the dental anchorage. Key words:ALT-RAMEC, A…

OrthodonticsMaxillary hypoplasiaHyraxbiologybusiness.industryClass iii malocclusionTreatment optionsCase ReportOrthodontics030206 dentistry:CIENCIAS MÉDICAS [UNESCO]medicine.diseasebiology.organism_classification03 medical and health sciences0302 clinical medicineUNESCO::CIENCIAS MÉDICASmedicineRapid maxillary expansion030212 general & internal medicineMalocclusionbusinessGeneral DentistryAngle class iii
researchProduct

Micropartículas de PLLA y CHT como andamiaje para la regeneración del cartílago articular: Modelo animal.

2020

espanolLa naturaleza avascular del cartilago ha supuesto que historicamente las lesiones osteocondrales hayan tenido mal pronostico. Una de las opciones de tratamiento para dichas lesiones es el uso de andamiajes, siendo superior respecto a otras tecnicas que consiguen un fibrocartilago como resultado. Hemos elaborado microesferas de PLLA y CHT para usarlos como andamiaje en lesiones osteocondrales producidas a conejos albinos New Zealand. Se distribuyeron grupos con diferentes proporciones de microesferas, asi como un grupo control con la lesion sin tratar. Se analizo tambien el cartilago nativo de la rodilla contralateral. Se evaluaron las muestras para establecer la calidad del cartilago…

Pharmacologybusiness.industryUNESCO::CIENCIAS MÉDICASFibrous cartilageTreatment optionsMedicine:CIENCIAS MÉDICAS [UNESCO]Nuclear medicinebusinessMicrosphereRevista Española de Cirugía Osteoarticular
researchProduct

Long term outcomes of pharmacological treatments for opioid dependence: does methadone still lead the pack?

2014

The aim of this review was to update and summarize the scientific knowledge on the long term outcomes of the different pharmacological treatment options for opioid dependence currently available and to provide a critical discussion on the different treatment options based on these results. We performed a literature search using the PubMed databases and the reference lists of the identified articles. Data from research show that the three pharmacological options reviewed are effective treatments for opioid dependence with positive long term outcomes. However, each one has its specific target population and setting. While methadone and buprenorphine are first line options, heroin-assisted tre…

Pharmacologymedicine.medical_specialtybusiness.industryTreatment optionsOpiate Substitution TreatmentHeroinHeroin-assisted treatmentOpioidmedicineLong term outcomesPharmacology (medical)businessPsychiatrymedicine.drugMethadoneBuprenorphineBritish Journal of Clinical Pharmacology
researchProduct

Penetrating aortic ulcer post migration of thoracic aortic endoprosthesis: Case report

2021

Introduction Thoracic endovascular aortic repair (TEVAR) is the first treatment option for many thoracic aortic pathologies. Especially after aortic dissections, it is possible to have progression during follow-up with appearance of new lesions on arterial wall. Herein, we report a case of Penetrating Aortic Ulcer (PAU) post release of Thoracic endoprosthesis. Presentation of case A 67-years-old male with hypertension and diabetes mellitus was followed at our hospital after an emergency procedure for Type B aortic dissection (TBAD) complicated by symptomatic large infrarenal AAA and treated with a proximal TEVAR plus chimney for left subclavian artery and PETTICOAT with EVAR for abdominal a…

Post releasemedicine.medical_specialtyTEVARbusiness.industrymedicine.medical_treatmentStentTreatment optionsmedicine.diseaseAortic diseaseProsthesisSettore MED/22 - Chirurgia VascolareSurgeryPenetrating atherosclerotic ulcerPenetrating atherosclerotic ulcermedicine.arteryCase reportcardiovascular systemmedicineThoracic aortaSurgeryArterial wallComplicated aortic B dissectionbusinessMigration endoprosthesis
researchProduct